Cargando…

Cancer Subtype Discovery Using Prognosis-Enhanced Neural Network Classifier in Multigenomic Data

OBJECTIVE: The main objective in studying large-scale cancer omics is to identify molecular mechanisms of cancer and discover novel biomedical targets. This work not only discovers the cancer subtypes in genome scale data by using clustering and classification but also measures their accuracy. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasudevan, Prasanna, Murugesan, Thangamani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088521/
https://www.ncbi.nlm.nih.gov/pubmed/30092720
http://dx.doi.org/10.1177/1533033818790509
Descripción
Sumario:OBJECTIVE: The main objective in studying large-scale cancer omics is to identify molecular mechanisms of cancer and discover novel biomedical targets. This work not only discovers the cancer subtypes in genome scale data by using clustering and classification but also measures their accuracy. METHODS: Initially, candidate cancer subtypes are recognized by max-flow/min-cut graph clustering. Finally, prognosis-enhanced neural network classifier is proposed for classification. We analyzed the heterogeneity and identified the subtypes of glioblastoma multiforme, an aggressive adult brain tumor, from 215 samples with microRNA expression (12 042 genes). The samples were classified into 4 different classes such as mesenchymal, classical, proneural, and neural subtypes owing to mutations and gene expression. The results are measured using the metrics such as silhouette width, biological stability index, clustering accuracy, precision, recall, and f-measure. RESULTS: Max-flow/min-cut clustering produces higher clustering accuracy of 88.93% for 215 samples. The proposed prognosis-enhanced neural network classifier algorithm produces higher accuracy results of 89.2% for 215 samples efficiently. CONCLUSION: From the experimental results, the proposed prognosis-enhanced neural network classifier is seen as an alternative, which is full of promise for cancer subtype prediction in genome scale data.